The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas

Annals of Surgery

Volumn 260, Issue 1, 2014, Pages 158-162

  Ellis, Ryan J ^a,b   Patel, Dhaval ^a   Prodanov, Tamara ^c   Nilubol, Naris ^a   Pacak, Karel ^c   Kebebew, Electron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

carotid body tumor; genetics; metastasis; paraganglioma; surgery

Indexed keywords

SUCCINATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; AGGRESSIVENESS; ARTICLE; BILATERAL CANCER; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CAROTID BODY TUMOR; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRANIAL NERVE INJURY; CRANIAL NEUROPATHY; DECISION MAKING; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DYSPHAGIA; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GERM LINE; GERMLINE MUTATION; HOARSENESS; HORNER SYNDROME; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHEOCHROMOCYTOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL APPROACH; SURGICAL MORTALITY; SYMPTOM; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; CAROTID BODY TUMOR; CHILD; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; GERM-LINE MUTATION; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUCCINATE DEHYDROGENASE; YOUNG ADULT;

EID: 84902271775     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000283     Document Type: Article

References (22)

1. Schipper J, Boedeker CC, Maier W, et al. [Paragangliomas in the head-/neck region. I: classification and diagnosis]. HNO. 2004;52:569-574; quiz 575.
2. Lee JH, Barich F, Karnell LH, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer. 2002;94:730-737.
3. Glenner GG, Grimley PM. Tumors of the Extra-Adrenal Paraganglion System (Including Chemoreceptors). Washington: Armed Forces Institute of Pathology; for sale by the American Registry of Pathology, Armed Forces Institute of Pathology; 1974.
4. Kleihues P, Cavenee WK, International Agency for Research on Cancer. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press; 2000.
5. SchwaberMK, GlasscockME, Nissen AJ, et al. Diagnosis and management of catecholamine secreting glomus tumors. Laryngoscope. 1984;94:1008-1015.
6. Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86:5210-5216.
7. Maier W, Marangos N, Laszig R. Paraganglioma as a systemic syndrome: pitfalls and strategies. J Laryngol Otol. 1999;113:978-982.
8. Pellitteri PK, Rinaldo A, Myssiorek D, et al. Paragangliomas of the head and neck. Oral Oncol. 2004;40:563-575.
9. Boedeker CC. Paragangliomas and paraganglioma syndromes. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2011;10:Doc03.
10. Langerman A, Athavale SM, Rangarajan SV, et al. Natural history of cervical paragangliomas: outcomes of observation of 43 patients. Arch Otolaryngol Head Neck Surg. 2012;138:341-345.
11. Jansen JC, van den Berg R, Kuiper A, et al. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer. 2000;88:2811-2816.
12. de Flines J, Jansen J, Elders R, et al. Normal life expectancy for paraganglioma patients: a 50-year-old cohort revisited. Skull Base. 2011;21:385-388.
13. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943-951.
14. Boedeker CC, Neumann HP, Maier W, et al. Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg. 2007;137:126-129.
15. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003;63:5615-5621.
16. Matro J, Giubellino A, Pacak K. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors. Horm Metab Res. 2013;45:147-153.
17. van Hulsteijn LT, Dekkers OM, Hes FJ, et al. Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J Med Genet. 2012;49:768-776.
18. Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3:92-102.
19. Fruhmann J, Geigl JB, Konstantiniuk P, et al. Paraganglioma of the carotid body: treatment strategy and SDH-gene mutations. Eur J Vasc Endovasc Surg. 2013;45:431-436.
20. O'Riordain DS, Young WF, Jr, Grant CS, et al. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg. 1996;20:916-921; discussion 922.
21. Wangberg B, Muth A, Khorram-Manesh A, et al. Malignant pheochromocytoma in a population-based study: survival and clinical results. Ann N Y Acad Sci. 2006;1073:512-516.
22. Zarnegar R, Kebebew E, Duh QY, et al. Malignant pheochromocytoma. Surg Oncol Clin N Am. 2006;15:555-571.